Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 2Sarcoma 1Myeloid 1Lymphoid 1Head & Neck 1CNS 1Breast 1

Conditions

Glioblastoma 11Brain Neoplasms 11Gliosarcoma 9Neuroblastoma 5Astrocytoma 5Oligodendroglioma 4Glioma 4Carcinoma, Renal Cell 4Sarcoma, Ewing 3Sarcoma 3Rhabdomyosarcoma 3Rhabdoid Tumor 3Recurrence 3Neoplasms, Germ Cell and Embryonal 3Central Nervous System Neoplasms 3Breast Neoplasms 3Wilms Tumor 2Prostatic Neoplasms 2Osteosarcoma 2Neurofibromatosis 2 2Neurofibromatosis 1 2Neoplasms 2Melanoma 2Medulloblastoma 2Ependymoma 2Carcinoma, Hepatocellular 2Vestibulocochlear Nerve Diseases 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Urinary Bladder Neoplasms 1

Interventions

Nivolumab 3Magnetic Resonance Spectroscopy 3Ipilimumab 3pembrolizumab 2Fluorodeoxyglucose F18 2FAPI-46 2Bevacizumab 2temsirolimus 1regorafenib 1aflibercept 1X-Rays 1Valproic Acid 1Specimen Handling 1Sirolimus 1Paclitaxel 1NEO212 1Immunoglobulin G 1IFL protocol 1Disulfides 1Cetuximab 1Carboplatin 1CTLA-4 Antigen 1Antineoplastic Protocols 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × Sirolimus × CNS × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡